Table 2.

HIV drugs associated with drug hypersensitivity

Class	Drug	Reaction	Hepatotoxicity	Frequency
NRTI	Zidovudine	Exanthema	Not reported	Rare
	Abacavir	Exanthema, HSR	Elevated LFTs hepatitis, liver failure	2.3–9% [23]
	Emtricitabine	Rash	Elevated LFTs	17% [134]
NNRTIs	Efavirenz	SJS, TENExanthema,	Elevated LFTs	0.1% [135] 4.6–20% [129]
	Nevirapine	Exanthema, TEN, SJS, HSR,	Elevated LFTs immune mediated hepatitis, liver failure	17–32% [49] 0.3–2% [49] 2–10% discontinuation [9]
	Etravirine	Rash, SJS, TEN	Elevated LFTs	16% [136] 2% discontinuation [72]
PIs	Tipranavir	Rash, dyslipidaemia	Elevated LFTs s, toxic hepatitis	2–14% [85] 2–6.4% [87]
	Atazanavir	Rash	Hyperbilirubinaemia	6% [137]
	Fosamprenavir	Rash, HSR	Elevated LFTs	1–19% [79] Discontinuation <1%
	Lopinavir	Rash	Elevated LFTs	2–4% [77]
	Darunavir	Rash, HSR	Elevated LFTs	6.7% [138] Rare
Entry inhibitors	Enfuvirtide	Injection site reactions, HSR	Not reported	Rare
	Maraviroc	Rash, cough,	Elevated LFTs	Rash [91,139]

HSR, hypersensitivity reaction; SJS, Stevens-Johnson syndrome; TEN, toxic epidermal necrolysis; LFTs, liver function tests.